Basic Information
| LncRNA/CircRNA Name | FOXD2-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:47432133-47434641 |
| Ensemble | ENSG00000237424 |
| Refseq | NR_026878 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Esophageal Squamous Cell Carcinoma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | ESCC tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | This study explored the impact of the lncRNA FOXD2-AS1 on cisplatin resistance in ESCC and its possible mechanisms. Upregulation of FOXD2-AS was detected in patients with ESCC and ESCC cells that are resistant to cisplatin. |
| Pubmed ID | 31558183 |
| Year | 2019 |
| Title | Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis. |
External Links
| Links for FOXD2-AS1 | GenBank HGNC NONCODE |
| Links for Esophageal Squamous Cell Carcinoma | OMIM COSMIC |